BOUDNÝ, Miroslav, Jana ZEMANOVÁ, PrashantKumar KHIRSARIYA, Marek BORSKÝ, Jan VERNER, Jana ČERNÁ, Alexandra OLTOVÁ, Václav ŠEDA, Marek MRÁZ, Josef JAROŠ, Zuzana JAŠKOVÁ, Michaela ŠPUNAROVÁ, Yvona BRYCHTOVÁ, Karel SOUČEK, Stanislav DRÁPELA, Marie KAŠPÁRKOVÁ, Jiří MAYER, Kamil PARUCH and Martin TRBUŠEK. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. Haematologica. PAVIA: FERRATA STORTI FOUNDATION, vol. 104, No 12, p. 2443-2455. ISSN 0390-6078. doi:10.3324/haematol.2018.203430. 2019.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
Authors BOUDNÝ, Miroslav (203 Czech Republic, belonging to the institution), Jana ZEMANOVÁ (203 Czech Republic, belonging to the institution), PrashantKumar KHIRSARIYA (356 India, belonging to the institution), Marek BORSKÝ (203 Czech Republic, belonging to the institution), Jan VERNER (203 Czech Republic, belonging to the institution), Jana ČERNÁ (203 Czech Republic, belonging to the institution), Alexandra OLTOVÁ (203 Czech Republic, belonging to the institution), Václav ŠEDA (203 Czech Republic, belonging to the institution), Marek MRÁZ (203 Czech Republic, belonging to the institution), Josef JAROŠ (203 Czech Republic, belonging to the institution), Zuzana JAŠKOVÁ (703 Slovakia, belonging to the institution), Michaela ŠPUNAROVÁ (203 Czech Republic, belonging to the institution), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Karel SOUČEK (203 Czech Republic, belonging to the institution), Stanislav DRÁPELA (203 Czech Republic, belonging to the institution), Marie KAŠPÁRKOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Kamil PARUCH (203 Czech Republic, belonging to the institution) and Martin TRBUŠEK (203 Czech Republic, guarantor, belonging to the institution).
Edition Haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2019, 0390-6078.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher Italy
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 7.116
RIV identification code RIV/00216224:14110/19:00108541
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3324/haematol.2018.203430
UT WoS 000499687600029
Keywords in English IN-VITRO; KINASE; CLL; PROLIFERATION; ACTIVATION; MUTATIONS; LETHALITY; OUTCOMES; IMPACT; MODEL
Tags 14110212, 14110517, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Marie Šípková, DiS., učo 437722. Changed: 20/2/2023 11:57.
Abstract
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently experience early progression of the disease. Development of alternative therapeutic approaches is, therefore, of critical importance. Here we report details of the anti-chronic lymphocytic leukemia single-agent activity of MU380, our recently identified potent, selective, and metabolically robust inhibitor of checkpoint kinase 1. We also describe a newly developed enantioselective synthesis of MU380, which allows preparation of gram quantities of the substance. Checkpoint kinase 1 is a master regulator of replication operating primarily in intra-S and G(2)/M cell cycle checkpoints. Initially tested in leukemia and lymphoma cell lines, MU380 significantly potentiated efficacy of gemcitabine, a clinically used inducer of replication stress. Moreover, MU380 manifested substantial single-agent activity in both TP53-wild type and TP53-mutated leukemia and lymphoma cell lines. In chronic lymphocytic leukemia-derived cell lines MEC-1, MEC-2 (both TP53-mut), and OSU-CLL (TP53-wt) the inhibitor impaired cell cycle progression and induced apoptosis. In primary clinical samples, MU380 used as a single-agent noticeably reduced the viability of unstimulated chronic lymphocytic leukemia cells as well as those induced to proliferate by anti-CD40/IL-4 stimuli. In both cases, effects were comparable in samples harboring p53 pathway dysfunction (TP53 mutations or ATM mutations) and TP53-wt/ATM-wt cells. Lastly, MU380 also exhibited significant in vivo activity in a xenotransplant mouse model (immunodeficient strain NOD-scid IL2R gamma(null)) where it efficiently suppressed growth of subcutaneous tumors generated from MEC-1 cells.
Links
LM2015063, research and development projectName: Národní infrastruktura chemické biologie (Acronym: CZ-­OPENSCREEN)
Investor: Ministry of Education, Youth and Sports of the CR
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1105/2018, interní kód MUName: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VI (Acronym: VýDiTeHeMA VI)
Investor: Masaryk University, Category A
NV15-33999A, research and development projectName: Vývoj nových nízkomolekulárních protinádorových léčiv na principu syntetické letality
PrintDisplayed: 28/3/2024 18:47